1177 BASELINE Phospho-Stat1 LEVEL IN PBMC IS A NON-INVASIVE BIOMARKER OF EARLY VIROLOGICAL RESPONSE TO TRIPLE THERAPY IN CHRONIC HCV INFECTION – ANRS C10–08 STUDY

2013 ◽  
Vol 58 ◽  
pp. S478
Author(s):  
P. Sultanik ◽  
A. Casrouge ◽  
C. Br'echot-Alanio ◽  
E. Mottez ◽  
L. Bousquet ◽  
...  
2013 ◽  
Vol 11 (1) ◽  
pp. 69-73
Author(s):  
Wafaa M. Ezzat ◽  
Yasser A. Elhosary ◽  
Nour A. Abdulla ◽  
Hala M. Raslan ◽  
Omneya M. Saleh ◽  
...  

2012 ◽  
Vol 26 (6) ◽  
pp. 325-329 ◽  
Author(s):  
Dina H Ziada ◽  
Sherif El Saadany ◽  
Mohamed Enaba ◽  
Medhat Ghazy ◽  
Azza Hasan

BACKGROUND: Hepatitis C virus (HCV) infection may induce insulin resistance (IR) irrespective of the severity of liver disease, and there is evidence of a central role for IR in failure to achieve sustained virological response (SVR) in HCV patients.OBJECTIVE: To assess IR as a predictor of the severity of hepatic fibrosis in Egyptian HCV patients, and its effect on early viral kinetics and virological response to HCV therapy.METHODS: A total of 140 chronic HCV patients were divided into two groups according to the homeostasis model assessment-IR (HOMA-IR). Group 1 consisted of 48 chronic HCV patients with HOMA-IR ≥2, and group 2 consisted of 92 chronic HVC patients without IR (HOMA IR <2). All patients were treated with combination therapy (pegylated interferon-alpha 2a plus ribavirin) for 48 weeks and studied for viral kinetics throughout the period of therapy.RESULTS: The study revealed that older age, higher body mass index and HOMA-IR≥2 were significantly associated with advanced fibrosis. Rapid virological response, complete early virological response and SVR were significantly lower in the IR-HCV group compared with the non-IR-HCV group. Univariate and multivariate analyses revealed that older age, fibrosis (F≥3), high viral load (>600,000 IU/mL) and HOMA-IR ≥2 were significantly associated with a lack of viral kinetics as well as SVR. However, HOMA-IR ≥2 was the main independent variable associated with lack of SVR. On the other hand, body mass index, plasma insulin level and HOMA-IR decreased significantly compared with starting levels in patients who achieved SVR. This suggests a cause and effect relationship between HCV infection and IR.CONCLUSION: IR in chronic HCV patients is associated with progressive fibrosis and slow viral kinetics, and could be a predictor for lack of rapid and early virological response. Therefore, HOMA-IR levels should be measured and improved before starting antiviral treatment.


2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
David Callau Monje ◽  
Niko Braun ◽  
Joerg Latus ◽  
Kerstin Amann ◽  
Mark Dominik Alscher ◽  
...  

Introduction.The HCV infection is a common disease with many chronically infected patients worldwide. So far, the standard therapy of a chronic HCV infection consisted of interferon as single therapy or in combination with ribavirin. After approval of the two protease inhibitors, boceprevir and telaprevir, the standard therapy for patients with genotype 1 changed. In patients with acute kidney injury (AKI) these therapies are not approved and have so far not been evaluated in studies.Case Report.In April 2012, a 58-year-old female was admitted due to a cryoglobulin-positive chronic HCV infection which had been treated with interferon and ribavirin. Currently, the patient was admitted because of severe complications with an acute kidney injury. We treated our patient successfully with a boceprevir based triple therapy.Conclusion.Limited data suggests that a therapy with ribavirin in patients with AKI seems to be safe under close monitoring. Our patient was treated successfully with a protease inhibitor based triple therapy. Nevertheless, it is necessary to plan an interventional study to evaluate the exact risk-benefit profile of triple therapy regimens in patients with AKI and hepatitis C.


2019 ◽  
Vol 17 (8) ◽  
pp. 44-47
Author(s):  
A. I. Fazulzyanova ◽  
◽  
S. V. Tkacheva ◽  
A. K. Khusainova ◽  
N. F. Gayfutdinov ◽  
...  

2017 ◽  
Vol 65 (4) ◽  
pp. 765-771 ◽  
Author(s):  
Prashant Pandya ◽  
Chaitanya Pant ◽  
Ryan Taylor ◽  
Olurinde Oni

The high cost associated with antiviral treatment for chronic hepatitis C virus (HCV) infection mandates further investigation in the context of preventing complications such as type 2 diabetes mellitus (DM2). We determined the cumulative incidence of DM2 in subjects with chronic HCV infection who received concomitant pegylated interferon (Peg-IFN) and ribavirin. We conducted a retrospective analysis of data obtained from Veterans Administrations Informatics and Computing Infrastructure (VINCI) to identify an adult cohort of patients without diabetes with chronic HCV infection who received Peg-IFN-based therapy between October 2001 and December 2011. Patients with history of HIV, hepatitis B infection, hepatocellular cancer (HCC), non-HCC cancers, and history of transplantation were excluded. Sustained virological response (SVR) was defined as negative HCV RNA 3 months after completion of therapy. Using Cox proportional hazards regression for multivariable analysis, we determined that patients who achieved SVR were at a significantly less risk of developing DM2. Adjusted survival rates showed that the responders' group was significantly less likely to develop DM2 over time (HR 0.60, CI 0.48 to 0.74, p<0.001). Peg-IFN-based therapy in chronic HCV patients that resulted in SVR significantly decreased the risk of developing DM2 and independently predicts the development of new onset disease after controlling for correlates of metabolic syndrome.


Sign in / Sign up

Export Citation Format

Share Document